Drug intelligence / Profile preview

puribaptide

Development stage: Unknown
Lead developer: Shaanxi Maike Aote Technology
Modality: Peptides
Administration: Intravenous

Overview

Puribaptide is a synthetic cyclic peptide and a platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor antagonist. Developed by Shaanxi Maike Aote Technology Co., Ltd., it is intended for the treatment of acute coronary syndrome (ACS) and for patients undergoing percutaneous coronary intervention (PCI). The drug works by binding to the GP IIb/IIIa receptor on the surface of platelets, which prevents the binding of fibrinogen and other adhesive ligands, thereby inhibiting platelet aggregation and thrombus formation. Puribaptide is administered via intravenous injection and has been evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and pharmacodynamic effects on platelet function and coagulation.

Other names: 普瑞巴肽

Targets

GPIIb/IIIa (Integrin alpha-IIb/beta-3)

Beyond the preview

Go deeper on puribaptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on puribaptide.

Explore the full profile